Resources

Rimonabant, the first in the new drug class of CB1 blockers, was found to improve hemoglobin A1c (HbA1c) levels, reduce lipid levels and blood pressure, and reduce weight and waist size, researchers reported.

Artery walls begin thickening as early as the midteen years in young people with type 1 diabetes.

Patients with type 2 diabetes who take the new incretin mimetic drug exenatide (Byetta) appear to achieve sustained glucose control and progressive weight reduction after 18 months of therapy.

Engaging in regular vigorous physical activity before pregnancy reduces the risk of gestational diabetes mellitus (GDM).

In 2003 alone, nearly 60% of new cases were obese, and an additional 30% were overweight.

Encapsulating islets cells with polyethylene glycol — may soon obviate the need for immunosuppression in islet cell transplantation.

Retinopathy can lead to blindness in people with diabetes and may occur far sooner than previously thought, possibly when patients are still in the prediabetes stage or when glucose levels are only slightly higher than normal.

In Controlling Lipid and Glucose Levels. The novel compound tesaglitazar (Galida) appears to be effective in reducing fasting glucose while decreasing triglyceride levels and increasing high-density lipoprotein (HDL) cholesterol levels.

Two-in-one pill shows a reduction in plasma lipid levels and glucose levels.

The diabetes drug metaglidasen was shown to control blood glucose levels without causing weight gain or edema, according to a mid-stage clinical trial.